Shandong Suncadia Medicine Co., Ltd.

This study tests an experimental drug called HRS-7058 in people with advanced pancreatic cancer that has a specific mutation in the KRAS gene (G12C). Participants must have already tried at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe i…

This Phase 3 trial tests whether the drug HRS-7535 can lower blood pressure better than a placebo in 648 adults with hypertension who are also overweight or obese. Participants will take the drug or placebo for up to 48 weeks, and researchers will measure changes in blood pressur…

This phase 2 trial tests an experimental pill called HRS-7085 in 48 adults with moderate to severe ulcerative colitis. Participants receive either a low dose, high dose, or placebo for several weeks. The study checks for safety, symptom improvement, and how the drug moves through…

This phase 3 trial is testing whether a new drug called HRS-8080, combined with dalpiciclib, works better than the standard treatment (fulvestrant plus dalpiciclib) for people with advanced breast cancer that has become resistant to hormone therapy. About 912 women aged 18-75 wit…

This study tests a new drug called HRS-6719 in people with advanced solid tumors that lack a gene called MTAP. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 120 participants will take part across multiple centers.

This Phase 3 trial compares a new drug, HRS-8080, against standard hormone therapies (like letrozole or tamoxifen) in 5,500 women with intermediate or high risk early breast cancer who have already completed at least 2 years of standard hormone treatment. The goal is to see if HR…

This study tests a new drug called HRS-1780 in 60 adults with primary aldosteronism, a condition where the adrenal glands make too much of a hormone that raises blood pressure. Participants will receive either HRS-1780 or a placebo to see if the drug safely lowers blood pressure …

This study tests an experimental drug called HRS-6208 combined with other cancer drugs (HRS-8080, fulvestrant, or letrozole) in 180 adults with advanced breast cancer that cannot be removed by surgery or has spread. The main goals are to find safe doses and see if the combination…

This early-stage study tests a new drug called HRS-3802 in 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug …

This Phase 3 trial tests whether HRS-1780 tablets can slow the decline of kidney function in nearly 2,000 adults with chronic kidney disease. Participants take the drug or a placebo alongside standard treatment. The study will track kidney health over 32 months to see if the drug…

This study tests a new drug called HRS-7058 combined with other anti-tumor medicines in 100 adults with solid tumors. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. Participants must be 18-75, in good general health, and have a life e…

This study tests several experimental drug combinations (HRS-2189, Fluvastatin, HRS-6209, HRS-8080, HRS-1358) in 300 people with advanced breast cancer that cannot be removed by surgery or has spread. The main goals are to check safety, find the best doses, and see if tumors shri…

This study tests a new drug called HRS-8080 against standard treatments chosen by doctors for women with advanced breast cancer that has worsened after hormone therapy. About 240 women aged 18-75 will take part. The main goal is to see if HRS-8080 can delay cancer growth longer t…

This study tests a new drug called HRS-7058 combined with other cancer drugs in 300 adults with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose and see if the combination is safe and shrinks tumors. Participants must have …

This early-stage trial is testing a new drug called HRS-7058 in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study aims to find the safest dose and see if the drug can shrink tumors or slow their growth. About 233 participants will r…

This study tests two drugs together (HRS-8080 and dalpiciclib) in people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combination can shrink tumors. About 146 women aged 18-75 will take part…

This study tests an experimental drug called HRS-7535 in 225 adults who have both heart failure (with mildly reduced or preserved pumping ability) and obesity. Participants will receive either the drug or a placebo for 36 weeks to see if it helps with weight loss and reduces infl…

This early-stage study tests a new drug called HRS-6208 in about 206 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow cancer growth. Participants…

This study tests an experimental drug called HRS-1301 in people with high cholesterol (dyslipidemia). About 189 participants will receive one of four doses of HRS-1301 or a placebo daily for 12 weeks. The main goal is to see how much the drug lowers 'bad' LDL cholesterol and to f…

This study is checking the long-term safety of a drug called HRS-1893 in 300 people with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. Participants have already taken HRS-1893 in earlier studies. The main goal is to see how many side effects occur and …

This study tests a new drug called HRS-1893 in 48 adults with heart failure where the heart pumps normally but is too stiff (heart failure with preserved ejection fraction). The main goal is to check safety and side effects, while also looking at changes in heart stress markers a…

This study tests a new drug called HRS-2129 in 168 Chinese adults with diabetic peripheral neuropathic pain (nerve pain from diabetes). Participants will receive either HRS-2129, a placebo, or the standard drug pregabalin to see if HRS-2129 reduces pain better than placebo. The t…

This early-stage trial tests a new drug called HRS-2129 in 200 people with moderate to severe knee osteoarthritis pain. Participants will receive either HRS-2129, a placebo, or an active comparator (celecoxib) to see if it reduces pain and improves joint function. The study is do…

This study tests a new drug called HRS-2129 for managing pain after abdominal surgery. About 360 adults having abdominal surgery will receive either HRS-2129, a placebo, or the standard painkiller tramadol. The goal is to see if HRS-2129 works better or has fewer side effects tha…

This early-stage study will check if two different tablet forms of the drug HRS-1893 are processed the same way in the body. Thirty-six healthy adults will take both versions and have blood tests to measure drug levels. The goal is to see if the two formulations are equivalent, n…

This early-stage study tests the safety and how the body processes a new drug called HRS-7156 in 66 healthy adults aged 18 to 55. The goal is to check for side effects and measure drug levels in the blood, not to treat heart failure. Participants must be healthy and not take any …

This early-stage trial in 16 healthy adults tests whether a new drug for high cholesterol, HRS-1301, changes how the body processes two common medicines: midazolam (a sedative) and atorvastatin (a cholesterol drug). Participants will take these drugs alone and together with HRS-1…

This study looks at how a new cholesterol-lowering tablet, HRS-1301, behaves in people with mild, moderate, or severe kidney problems compared to healthy volunteers. The goal is to understand if kidney function changes how the drug works, so doctors can give the right dose. About…